Celldex Therapeutics Stock Is Believed To Be Significantly Overvalued

Retrieved on: 2021-06-20 04:52:30

Tags for this article:

Click the tags to see associated articles and topics

Celldex Therapeutics Stock Is Believed To Be Significantly Overvalued. View article details on hiswai:

Excerpt

Celldex Therapeutics has a cash-to-debt ratio of 56.15, which is better than 68% of the companies in Biotechnology industry. GuruFocus ranks the ...

Article found on: www.gurufocus.com